GlassScriptPhysician profile
Joseph A Marotta
NPI 1750332656
$19,268.09
in general payments reported to CMS, 2019-2025
57 companies · $2,157 in 2025
The $2,157 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,567 · 2020: $3,320 · 2021: $3,631 · 2022: $3,449 · 2023: $2,261 · 2024: $1,882 · 2025: $2,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,300.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,514.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,567.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,222.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,064.93 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $998.71 | 2021-2025 | |
| Axsome Therapeutics, INC. | $858.67 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $855.62 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $769.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $744.53 | 2019-2025 | Belsomra, Verquvo, Gardasil 9 |
| Allergan, INC. | $664.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $662.94 | 2019-2022 | |
| Amarin Pharma, INC. | $662.13 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $651.01 | 2019-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $620.69 | 2019-2025 | |
| Amgen INC. | $568.44 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Marotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.